ZYUS Life Sciences Corp (@ZYUSCorp) header
ZYUS Life Sciences Corp (@ZYUSCorp) profile picture

#ZYUS (TSXV: ZYUS) is a clinical-stage life sciences company developing novel, non-opioid therapies for chronic & neuropathic pain.

Saskatoon, Saskatchewan
Joined January 2019
Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)Photo by ZYUS Life Sciences Corp (@ZYUSCorp)
ZYUS Life Sciences announces positive topline results from the Phase 2a UTOPIA-1 trial evaluating Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe cancer-related pain. bit.ly/4hjmI #ZYUS #NonOpioid #PainManagement #Cancer
3
28
#ZYUS that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 trial evaluating efficacy of Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain. zyus.com/2026-04-16-ZYUS-Lif… #ClinicalTrials #Oncology
1
14
ZYUS Life Sciences Announces Cancellation of LIFE Offering and Launch of Private Placement zyus.com/2026-02-24-ZYUS-Lif…
17
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units bit.ly/4jDmHYm #ZYUS #clinicalresearch #Lifesciences
21
ZYUS (TSXV: ZYUS) today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain. bit.ly/3LDo7Fz #LifeSciences #ClinicalTrials
24
#ZYUS Life Sciences Corp announced a key milestone in its ongoing Phase 2a UTOPIA-1 trial, with patient enrollment reaching 25%. zyus.com/news-and-events/new… #ClinicalTrials #Oncology #Innovation #NonOpioid #ZYUSLifeSciences #PainManagement #ZYUS #CancerResearch
31
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment #ZYUS #TSXVZYUS #InvestorNews #LifeSciences zyus.com/news-and-events/new…
28
ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured Promissory Note zyus.com/news-and-events/new… #ZYUS #LifeSciences #Biotech #ClinicalResearch #CannabinoidScience #PainManagement
18
Milestone for #ZYUS announced the activation of two additional clinical sites in its Phase 2a UTOPIA-1 cancer pain trial. Now 3 active sites enrolling patients across Canada. zyus.com/news-and-events/new… #cancerpain #Clinicaltrial #TSXV #LifeSciences
31
#ZYUS announces activation of Centre Hospitalier de l'Université de Montréal as the first site in its Phase 2a UTOPIA-1 trial for cancer pain. Advancing non-opioid innovation. bit.ly/4fUstCN #ClinicalTrial #Oncology #PainManagement #Biotech #CancerResearch
40
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug bit.ly/3FjC6xb #ZYUS #Phase2Trial #Cannabinoids #InnovativeMedicine #OncologyResearch #PainManagement #ClinicalTrial #PressRelease #LifeSciences #Biotechnews
34
1
1
2
128
ZYUS is pleased to announce receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human Clinical Trial for its lead drug product candidate, Trichomylin® softgels. #ZYUS #HealthcareInnovation #CannabinoidTherapies #ChronicPain
1
78
📣 Exciting news from ZYUS Life Sciences Corp zyus.com/news-and-events/new… #zyus #PressRelease #news #lifesciences #Innovation – at Saskatoon, Saskatchewan
59
ZYUS Life Sciences Corp retweeted
Brent Zettl, President & CEO, @ZYUSCorp (TSXV:ZYUS), and his team joined us to close the market and celebrate the Company’s listing on TSX Venture Exchange. $ZYUS is a Canadian life sciences company committed to reinventing the treatment of chronic and neuropathic pain by harnessing the therapeutic properties of cannabinoid formulations.
2
3
923
#ZYUS is pleased to welcome renowned business leader, Wayne Brownlee to ZYUS’ Board of Directors. #ZYUS #BusinessNews #PressRelease #TSXV #clinicalresearch – at Saskatoon, Saskatchewan
2
58
#ZYUS commenced trading today on the TSX Venture Exchange (#tsxv), under the ticker symbol “ZYUS”. . . . #businessnews #canadiannews #lifesciences #stockmarket #stockexchange #trading – at Saskatoon, Saskatchewan
2
164
#ZYUS Life Sciences Corporation (the “Company”) has been approved by the TSX Venture Exchange (“TSX-V”) to commence trading on Monday, June 19, 2023, under the ticker symbol “ZYUS”. #TSXV bit.ly/46bWoBt
1
77
ZYUS Life Sciences Corporation Announces Completion of RTO #zyus #Biotechnology #RTO #PressRelease #CanadaNewsToday #lifesciences #clinicalresearch bit.ly/45WFCWJ – at Saskatoon, Saskatchewan
2
71